INTRODUCTION {#s1}
============

Ductal carcinoma in situ (DCIS) comprises a heterogeneous group of neoplastic lesions confined to the breast ducts \[[@R1], [@R2]\], which subject to clonal proliferation of epithelial malignant cells yet does not exhibit stromal invasion into adjacent breast stroma under microscopic examination. The increased prevelance of mammographic screening has tremendously changed the situation where DCIS had been underdiagnosed, and the past two decades witnessed the dramatic increase of detection rate. The 10-year cancer-specific survival of DCIS reached over 95%, indicating that early diagnosis would exert substantial influence on prognosis \[[@R3]\]. However, the heterogeneity of DCIS warrants comprehensive investigations into the molecular mechanisms to enlighten management of this disease \[[@R4]\].

Traditionally, the diagnosis of DCIS relied on mammography and clinic pathologic findings \[[@R5]\]. However, the accuracy suffered from high false positive rate and high false negative rate, resulting in under- or over-treatment of DCIS \[[@R6]\]. Therefore, characterization of molecular signatures holds the promise for improving diagnosis of DCIS. Multiple lines of evidence demonstrated that diagnosis, prognosis and therapy prediction gain remarkable improvement from molecular signature \[[@R7], [@R8], [@R9]\], particularlyin identifying risk factors and early phase of carcinogenesis. Another compelling advantage of molecular signature resides in its non-invasive operation and relatively low cost, rendering it a promising method for seeking predictive and therapeutic biomarkers.

Microarray has been employed in characterizing themolecular mechanism of DCIS \[[@R10], [@R11], [@R12]\]. Several expression profiling researches of DCIS have been released, most of which were designed to identify key candidate genes implicated in the progression of DCIS to invasive ductal breast cancer (IDC) \[[@R13]\]. In this research, we collected 14 microarray data from microarray dataset: normal ductal cells from 5 patients; 9 surgical specimens with DCIS and proceeded several of bioinformatics analysis to recognize the molecular mechanism of DCIS. Gene with expression different between normal cells and cancer cells were identified. *MAD2L1*, *CDK1* and *ACACB* exhibit significantly distinctive expression patterns and may be highly involved in cacer related pathways of breast cancer, DCIS. Furthermore, docking analysis revealed that CDK1, a potential target of DCIS, has active site complementary with three antibiotic drugs, Pomalidomide and the Rosoxacin, indicating novel pharmacological utility of these drugs.

RESULTS {#s2}
=======

Analysis of DEGs {#s2_1}
----------------

The expression profile were preprocessed and then analyzed by Affy package in R language. Total genes were screened. Cassette figures after data standardization was shown in Figure [1A](#F1){ref-type="fig"}. The alignment of black dots on the same line indicates good standardization.

![Data process\
**(A)** data distribution after normalization; **(B)** Hierarchical cluster dendrogram of DEGs; **(C)** The DEGs in breast cancer in situ compared with those in normal samples](oncotarget-08-61998-g001){#F1}

Hierarchy cluster analysis demonstarted that the 9 breast cancer in situ samples and the 5 normal samples showed different distribution (Figure [1B](#F1){ref-type="fig"}). The result revealed that grouping was reasonable and the data can be directly applied to further analysis. A total of 649 DEGs were identified in normal ductal cells obtain from DCIS patients. There are 224 up-regulated genes and 425 down-regulated genes (Figure [1C](#F1){ref-type="fig"}). The top ten up-regulated genes (with the highest log-transformed fold change) were *CEACAM6*, *S100P*, *RRM2*, *COL10A1*, *KMO*, *TFAP2B*, *SDC1*, *COMP*, *KIAA0101* and *GJB2*. The top ten down-regulated genes (with the smallest log-transformed fold change) were *CIDEC*, *PCOLCE2*, *HSPB7*, *ACVR1C*, *PLIN4*, *TUSC5*, *GPD1*, *TIMP4*, *LEP* and *CIDEA* (Table [1](#T1){ref-type="table"}).

###### The top 10 most up and downregulated genes

  Upregulated   Downregulated                                   
  ------------- --------------- ---------- --------- ---------- ----------
  CEACAM6       7.76695         0.000179   CIDEA     -6.50126   0.000733
  S100P         7.438669        0.002028   LEP       -6.49356   0.00252
  RRM2          6.625876        0.000365   TIMP4     -6.43726   0.001675
  COL10A1       6.207364        4.15E-05   GPD1      -6.30837   0.000772
  KMO           6.034898        0.001794   TUSC5     -6.28374   0.000312
  TFAP2B        5.35991         0.003991   PLIN4     -6.16579   0.002251
  SDC1          5.207596        0.002872   ACVR1C    -5.96447   0.000369
  COMP          5.057335        0.000294   HSPB7     -5.8322    0.001175
  KIAA0101      4.972437        0.003068   PCOLCE2   -5.80062   0.003171
  GJB2          4.972225        0.004187   CIDEC     -5.78743   0.000647

Function and pathway enrichment analysis {#s2_2}
----------------------------------------

A total of 224 up-regulated genes and 425 down-regulated genes were uploaded to DAVID for GO enrichment (p \< = 0.05 as significant). Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"} showed the top enriched GO terms of up- and down-regulated genes separately. The up-regulated genes were mainly enriched in cell cycle phase, M phase, mitosis, nuclear division, mitotic cell cycle, M phase of mitotic cell cycle, organelle fission, cell division, cell cycle process and cell cycle (Table [2](#T2){ref-type="table"}), whereas the down-regulated genes were over-represented in response to endogenous stimulus, response to hormone stimulus, regulation of lipid metabolic process, plasma membrane part, plasma membrane, response to peptide hormone stimulus, response to organic substance, response to insulin stimulus, lipid particle and cell fraction, etc. (Table [3](#T3){ref-type="table"}). The KEGG pathways of up- and downregulated genes were summarized in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. The upregulated genes were mainly enriched in Cell cycle, Oocyte meiosis, Progesterone-mediated oocyte maturation, p53 signaling pathway and Systemic lupus erythematosus (Table [4](#T4){ref-type="table"}). Down-regulated genes were related to Glycerolipid metabolism, PPAR signaling pathway, Fatty acid metabolism, Pyruvate metabolism, Insulin signaling pathway, Glycolysis / Gluconeogenesis, Adipocytokine signaling pathway, Histidine metabolism, Propanoate metabolism and Retinol metabolism (Table [5](#T5){ref-type="table"}).

![Most significantly enriched GO terms of DEGs according P value](oncotarget-08-61998-g002){#F2}

###### The enriched GO terms of the up-regulation DEGs

  Term                                       Count   P Value    Genes
  ------------------------------------------ ------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0022403∼cell cycle phase                37      3.26E-20   PRC1, BLM, NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDC7, CDK1, KIF11, MKI67, SGOL2, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, CDKN3, SMC4, CCNB1, INHBA, MAD2L1, CCNB2, FANCD2, ZWINT, CKS2, BUB1B, KPNA2
  GO:0000279∼M phase                         33      1.85E-19   PRC1, NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDK1, KIF11, MKI67, SGOL2, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, FANCD2, ZWINT, CKS2, BUB1B, KPNA2
  GO:0007067∼mitosis                         27      4.93E-18   NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDK1, KIF11, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, ZWINT, BUB1B
  GO:0000280∼nuclear division                27      4.93E-18   NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDK1, KIF11, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, ZWINT, BUB1B
  GO:0000278∼mitotic cell cycle              33      6.08E-18   PRC1, BLM, NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDC7, CDK1, KIF11, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, CDKN3, SMC4, CCNB1, INHBA, CCNB2, MAD2L1, ZWINT, BUB1B, KPNA2
  GO:0000087∼M phase of mitotic cell cycle   27      7.75E-18   NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDK1, KIF11, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, ZWINT, BUB1B
  GO:0048285∼organelle fission               27      1.35E-17   NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDK1, KIF11, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, ZWINT, BUB1B
  GO:0051301∼cell division                   29      7.91E-17   PRC1, NEK2, ANLN, PTTG1, LLGL2, FAM83D, CCNE2, CCNA2, CDCA5, ASPM, HELLS, CDCA3, CDC7, CDK1, KIF11, SGOL2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, UBE2C, SMC4, CCNB1, CCNB2, MAD2L1, ZWINT, CKS2, BUB1B
  GO:0022402∼cell cycle process              38      1.12E-16   PRC1, BLM, NEK2, AURKA, ANLN, PTTG1, FAM83D, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDC7, CDK1, KIF11, MKI67, SGOL2, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, UBE2C, CDKN3, SMC4, CCNB1, INHBA, MAD2L1, CCNB2, FANCD2, ZWINT, CKS2, BUB1B, KPNA2, BARD1
  GO:0007049∼cell cycle                      43      7.23E-16   PRC1, BLM, NEK2, ANLN, AURKA, PTTG1, LLGL2, FAM83D, CCNE2, FANCI, CCNA2, CDCA5, HELLS, ASPM, CDCA3, CDC7, CDK1, KIF11, MKI67, SGOL2, DLGAP5, TPX2, CENPF, NUSAP1, BIRC5, CENPE, NDC80, PBK, CDKN3, UBE2C, SMC4, CCNB1, INHBA, UHRF1, MAD2L1, CCNB2, MAPK13, FANCD2, ZWINT, CKS2, BUB1B, KPNA2, BARD1
  GO:0007059∼chromosome segregation          13      4.59E-10   NEK2, SGOL2, DLGAP5, NUSAP1, CENPF, NDC80, CENPE, BIRC5, PTTG1, SMC4, MAD2L1, ZWINT, CDCA5

###### The enriched GO terms of thedown-regulation DEGs

  Term                                                          Count   P Value    Genes
  ------------------------------------------------------------- ------- ---------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0009719∼response to endogenous stimulus                    33      2.55E-10   CAV2, RBP4, CAV1, STAT5A, TACR1, ALDOC, PPARG, PFKFB1, FOXO1, PDE3B, GNG11, TIMP4, GNG12, ACVR1C, PRKAR2B, SORBS1, ANGPT1, GNG2, SIK2, GHR, TXNIP, IRS2, CRYAB, ACADS, CDO1, PCK1, LEP, GNAL, PLA2G4A, ADM, ALDH2, TGFBR3, CA4
  GO:0009725∼response to hormone stimulus                       31      4.25E-10   CAV2, RBP4, CAV1, STAT5A, TACR1, PPARG, PFKFB1, FOXO1, PDE3B, GNG11, TIMP4, GNG12, ACVR1C, PRKAR2B, SORBS1, ANGPT1, GNG2, SIK2, GHR, TXNIP, IRS2, CRYAB, ACADS, CDO1, PCK1, LEP, PLA2G4A, ADM, ALDH2, TGFBR3, CA4
  GO:0019216∼regulation of lipid metabolic process              16      1.89E-08   CAV1, IRS2, THRB, STAT5A, PPARG, MLXIPL, CIDEA, PDE3B, PNPLA2, ACACB, LEP, AGTR1, PLA2G4A, ACSL1, SORBS1, BMP6
  GO:0044459∼plasma membrane part                               88      3.71E-08   DLC1, CYB5R3, GYPC, TLN2, TSPAN4, TACR1, FERMT2, CLDN5, TSPAN7, CPEB1, KCNIP2, ITSN1, TENC1, DDR2, AMOTL2, CALB2, ACVR1C, LNPEP, EDNRB, AGTR1, GPC3, SDPR, GNG2, SLC4A4, GPIHBP1, SAMD4A, GHR, TYRO3, PTGER3, F10, LIFR, SLC7A10, SSPN, NCAM1, TNS1, CD36, EGFLAM, PGM5, PTRF, SGCG, CD34, CD99L2, CA4, JAM2, STBD1, FXYD1, CAV2, FGFR1, PALM, CAV1, EMCN, GNAI1, ENPP2, ADCYAP1R1, MRAS, MMD, MME, GNG11, GNG12, ALDH3A2, SLC29A1, SORBS1, PPL, DMD, SYN2, ADRA2A, PRIMA1, RASA3, EHD2, PTPRB, KL, MAOA, KCNB1, ITGA1, ANXA1, NPR1, ATP1A2, LYVE1, TMEM47, SLC16A7, ITGA7, NTRK2, SPTBN1, SCN4B, TGFBR3, PDZD2, SCARA5, LIPE
  GO:0005886∼plasma membrane                                    127     2.11E-07   DLC1, PLXNA4, GLDN, TSPAN4, TSPAN7, ITSN1, AMOTL2, CALB2, AGTR1, ELTD1, GNG2, SLC4A4, SAMD4A, TYRO3, IRS2, F10, CRYAB, LIFR, PNPLA2, SSPN, NCAM1, TNS1, CD36, EGFLAM, PGM5, KCNT2, PTRF, CD34, CD300LG, EMP1, ABCA8, FXYD1, CAV2, GPR146, FGFR1, PALM, EMCN, CAV1, MRAP, GNAI1, ENPP2, ADCYAP1R1, MRAS, MMD, AKAP12, MME, NRN1, SLC29A1, CDC42EP2, PPL, DMD, ADRA2A, PRIMA1, STX11, LPL, KLB, MAOA, KCNB1, ITGA1, MCAM, PCDH19, PCDH18, LYVE1, ITGA7, NTRK2, SPTBN1, TGFBR3, PDZD2, SCARA5, CYB5R3, GYPC, TLN2, TACR1, FERMT2, CLDN5, CPEB1, KCNIP2, TENC1, DDR2, ACVR1C, LNPEP, EDNRB, SPRY2, WISP2, GPC3, SDPR, QKI, CAT, GPIHBP1, GHR, PTGER3, STXBP1, SLC7A10, PCDH9, GNAL, SGCG, CD99L2, CA4, PCYOX1, JAM2, STBD1, CHL1, AOC3, GNG11, GNG12, ZBTB16, ALDH3A2, RGMA, ACSL1, SORBS1, PLIN4, SYN2, RASA3, PPAP2B, EHD2, PTPRB, PLA2G16, KL, ANXA1, NPR1, ATP1A2, P2RY12, TMEM47, SLC16A7, SCN4B, LIPE, GPR116
  GO:0043434∼response to peptide hormone stimulus               17      2.37E-07   RBP4, CAV2, IRS2, STAT5A, PPARG, PFKFB1, FOXO1, PDE3B, TIMP4, CDO1, PCK1, ACVR1C, LEP, ADM, SORBS1, SIK2, GHR
  GO:0010033∼response to organic substance                      38      9.90E-07   CAV2, RBP4, CAV1, STAT5A, TACR1, ALDOC, PFKFB1, PPARG, PDE3B, FOXO1, GNG11, TIMP4, GNG12, ACVR1C, PRKAR2B, ACSL1, SORBS1, GSN, GNG2, ANGPT1, SIK2, GHR, TXNIP, IRS2, CRYAB, ACADS, LIFR, CDO1, PCK1, LEP, GNAL, PLA2G4A, ADM, HSPB7, HSPB2, ALDH2, TGFBR3, CA4
  GO:0032868∼response to insulin stimulus                       13      1.69E-06   RBP4, IRS2, PFKFB1, PPARG, FOXO1, PDE3B, PCK1, ACVR1C, LEP, ADM, SORBS1, SIK2, GHR
  GO:0005811∼lipid particle                                     6       1.42E-05   CAV2, CAV1, PLIN1, PLIN4, CIDEA, PNPLA2
  GO:0007167∼enzyme linked receptor protein signaling pathway   22      1.89E-05   TXNIP, FGFR1, BMP2, IRS2, NDN, KL, STAT5A, ADCYAP1R1, LIFR, FOXO1, DDR2, CHRDL1, SORBS1, NTRK2, GDF10, SPTBN1, TGFBR3, ANGPT1, FGF2, SIK2, BMP6, GHR
  GO:0000267∼cell fraction                                      47      2.14E-05   CAV2, FGFR1, CAV1, MMD, MME, PDE3B, NMB, ITSN1, LNPEP, SLC29A1, PRKAR2B, EDNRB, WISP2, ACSL1, FMO2, DMD, CYP26B1, GPX3, LMOD1, RAPGEF3, EHD2, SAMD4A, GPD1, F10, CRYAB, KL, ITGA1, FADS3, GYG2, ATP1A2, SOD3, PCK1, PLA2G4A, LYVE1, CD36, PTRF, DGAT2, ADM, SLC16A7, PYGL, FBLN5, CLIC5, HSPB2, CA4, STBD1, EMP1, PC

###### The enriched pathways of the up-regulation DEGs

  Term                                               Count   P Value    Genes
  -------------------------------------------------- ------- ---------- --------------------------------------------------------------
  hsa04110:Cell cycle                                9       1.49E-04   CDC7, CCNE2, CCNB1, CDK1, MAD2L1, CCNB2, BUB1B, PTTG1, CCNA2
  hsa04114:Oocyte meiosis                            7       0.002418   CCNE2, CCNB1, CDK1, MAD2L1, CCNB2, AURKA, PTTG1
  hsa04914:Progesterone-mediated oocyte maturation   6       0.004289   CCNB1, CDK1, MAD2L1, CCNB2, MAPK13, CCNA2
  hsa04115:p53 signaling pathway                     5       0.01018    CCNE2, CCNB1, CDK1, CCNB2, RRM2
  hsa05322:Systemic lupus erythematosus              5       0.03529    HIST1H2BD, HIST1H2BE, HIST2H2BE, HIST1H2BH, HIST1H4J

###### The enriched pathways of the down-regulation DEGs

  Term                                       Count   P Value    Genes
  ------------------------------------------ ------- ---------- ----------------------------------------------------------------------
  hsa00561:Glycerolipid metabolism           8       1.29E-04   LPL, DGAT2, ALDH2, MGLL, GPAM, PPAP2B, ALDH3A2, AGPAT2
  hsa03320:PPAR signaling pathway            9       3.49E-04   LPL, CD36, ACSL1, SORBS1, PLIN1, PPARG, ACADL, PCK1, ANGPTL4
  hsa00071:Fatty acid metabolism             6       0.003354   ACSL1, ACADS, ADH1C, ALDH2, ADH1B, ACADL, ALDH3A2
  hsa00620:Pyruvate metabolism               6       0.003354   ALDH2, ACACB, ACSS2, ALDH3A2, PC, PCK1
  hsa04910:Insulin signaling pathway         10      0.007669   PRKAR2B, IRS2, INPP5K, SORBS1, PYGL, PDE3B, FOXO1, ACACB, LIPE, PCK1
  hsa00010:Glycolysis / Gluconeogenesis      6       0.018507   ALDOC, ADH1C, ALDH2, ADH1B, ACSS2, ALDH3A2, PCK1
  hsa04920:Adipocytokine signaling pathway   6       0.028403   LEP, IRS2, CD36, ACSL1, ACACB, PCK1
  hsa00340:Histidine metabolism              4       0.037481   ASPA, MAOA, ALDH2, ALDH3A2
  hsa00640:Propanoate metabolism             4       0.04814    ALDH2, ACACB, ACSS2, ALDH3A2
  hsa00830:Retinol metabolism                5       0.049434   DHRS3, DGAT2, CYP26B1, ADH1C, ADH1B, RDH5

Analysis of PPI network {#s2_3}
-----------------------

Initially, to get PPI data, we uploaded 478 DEGs to STRING website. Next, the samples whose PPI score above 0.4 were selected to construct PPI networks. The PPI networks of up- and down-regulated DEGs were displayed in Figure [3](#F3){ref-type="fig"}. The up-regulated network was created with 182 nodes and 486 edges (Figure [3A](#F3){ref-type="fig"}). The proteins cyclin dependent kinase 1 (CDK1, degree = 41), cyclin B2 (CCNB2, degree = 36), and MAD2 mitotic arrest deficient-like 1 (MAD2L1, degree = 36) were hub nodes in this network. The down-regulated PPI network was constructed with 262 nodes and 633 edges (Figure [3B](#F3){ref-type="fig"}). The protein superoxisome proliferator activated receptor gamma (PPARG, degree = 32), acetyl-CoA carboxylase beta (ACACB, degree = 29) and catalase (CAT, degree = 27) were hub nodes in this network (Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). These genes are also enriched in Go terms and KEGG pathway excluding *CAT* gene.

![PPI network of DEGs obtained from the STRING database\
**(A)** PPI network of DEGs of upregulation DEGs; **(B)** PPI network of DEGs of downregulation DEGs; **(C)** Hub nodes in the PPI network constructed with upregulated genes; **(D)** Hub nodes in the PPI network constructed with downregulated genes.](oncotarget-08-61998-g003){#F3}

Key genes filter and survival analysis {#s2_4}
--------------------------------------

To visualize gene expression level of the 5 most intersecting genes: *CDK1*, *CCNB2*, *MAD2L1*, *PPARG*, and *ACACB*, we used pheatmap package implemented in R to generate a heatmap (Figure [4](#F4){ref-type="fig"}) to detect the gene expression differences between normal ductal cells and DCIS. In this step, we targeted three genes: *MAD2L1*, *CDK1* and *ACACB*, because they showed the most significant distinction in gene expression profile.

![Heatmap of hub genes in PPI network and the corresponding enriched GO and KEGG terms](oncotarget-08-61998-g004){#F4}

Docking the ZINC database {#s2_5}
-------------------------

The 26,504 molecules of the lead-like subset of the ZINC database were docked into the structure of CDK1. The molecules were scored for receptor complementarity based on the sum of their van der Waals \[using the AMBER potential\] and electrostatic interaction energies \[using ligand probe charges in an electrostatic potential calculated by DelPhi, corrected for ligand desolvation (Figure [5](#F5){ref-type="fig"}). Based on their docking scores, the compounds were ranked from best to worst fitting, and all of the compounds prioritized for experimental testing were selected from the top-ranking 500 molecules, representing 0.05% of the docked library. In addition, these molecules were inspected visually for features not captured in the docking calculation, such as chemical diversity, actual commercial availability, and an overall balance between polar and nonpolar complementarily to the binding site. Finally, 9 molecules were selected for the further study (Table [6](#T6){ref-type="table"}). Moreover, a structure alignment between the selected 9 compounds and the members of the DrugPort containing 1492 approved drugs were performed to find FDA approved drugs which can inhibit the activity of the CDK1. Consequently, Aminophenazone, Pomalidomide and the Rosoxacin shared large similarity to the structures of the Zinc210393, Zinc 312408 and Zinc5316172, respectively, suggesting that these compounds can bind to the active site of the CDK1 with the similar poses of the Zinc210393, Zinc 312408 and Zinc5316172 (Figure [6](#F6){ref-type="fig"}). It was postulated that Aminophenazone, Pomalidomide and the Rosoxacin might have therapeutic value in treating diseases derived from the dysfunction of CDK1.

![The structure of the CDK1\
The active site of CDK1 identified by the FTMAP server was depicted by lime circle.](oncotarget-08-61998-g005){#F5}

###### Top-10 docking result

  ZINC ID        Chemicals                            Score (kcal/mol)
  -------------- ------------------------------------ ------------------
  Zinc320022     ![](oncotarget-08-61998-fx001.jpg)   -15.2
  Zinc19796871   ![](oncotarget-08-61998-fx002.jpg)   -16.1
  Zinc210393     ![](oncotarget-08-61998-fx003.jpg)   -14.2
  Zinc368131     ![](oncotarget-08-61998-fx004.jpg)   -15.6
  Zinc123806     ![](oncotarget-08-61998-fx005.jpg)   -16.7
  Zinc372776     ![](oncotarget-08-61998-fx006.jpg)   -15.2
  Zinc291147     ![](oncotarget-08-61998-fx007.jpg)   -13.9
  Zinc5316172    ![](oncotarget-08-61998-fx008.jpg)   -14.7
  Zinc312408     ![](oncotarget-08-61998-fx009.jpg)   -15.6
  Zinc42568      ![](oncotarget-08-61998-fx010.jpg)   -14.5

![The structures of the Aminophenazone, Pomalidomide and Rosoxacin\
The Aminophenazone was a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013. Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.](oncotarget-08-61998-g006){#F6}

DISCUSSION {#s3}
==========

In our research, the gene expression profile information of GSE21422 was downloaded from GEO database to determine DEGs between DCIS and healthy breast tissues utilizing bioinformatics tools. Entirely, 649 DEGs including 224 up- and 425 down-regulated genes were selected. The functional enrichment analysis results revealed that up regulated genes were involved in cell cycle and Oocyte development, p53 signaling pathway, while down-regulated genes were mainly enriched in the lipid metabolism and PPAR pathway.

Moreover, Five genes were hub nodes in PPI networks. Expression profile showed that *MAD2L1*, *CDK1* and *ACACB*exhibit most distinctive expression pattern. These DEGs and their related functions may be involved in DCIS progression. MAD2L1, also termedas Mitotic Arrest Deficient 2-like 1, is an essential component in mitosis when chromosomes are detached to the mitotic spindle that maintains openning of chromosomes, and is involved in the spindle checkpoint during mitosis \[[@R17], [@R18], [@R19]\]. It has great potential in assessment of prognosis and may serve as tumor biomarkers in breast cancer \[[@R20]\]. In this research, we specifically identified a subset of DCIS in which MAD2L1 plays as a biomarker. CDK1 is a member of the Ser/Thr protein kinase family \[[@R21], [@R22]\]. In this study, over-expression of CDK1 was enriched in Oocyte development and p53 signaling pathwayindicating that overexpression of CDK1 may promote DCIS progression by p53 signaling. Additionally, ACACB is a complex multifunctional enzyme system which determines the catalytic rate of fatty acid oxidation \[[@R23], [@R24], [@R25]\]. However, current studies characterizing the function of ACACB in DCIS is rare. The current research revealed that the ectopic expression of ACACB reminiscent of its clinical value as a diagnostic indicator of DCIS \[[@R26], [@R27], [@R28]\]. We also demonstrated that the active site of CDK1 is complementary with three FDA approved drugs Aminophenazone, Pomalidomide and the Rosoxacin, indicating novel pharmacological value beyond their antibiotic function. Although more thorough researches are warranted, anti-cancer therapeutical potency of these three drugs in breast cancer may remain to be discovered.

In conclusion, our research identified a general amount of 478 DEGs which may be associated with pathogenesis and progression of DCIS. Functional pathway enrichment analysis and PPI network construction were combined to identify three genes with significantly distinctive expression pattern and highly connecting with cancer related pathways. These genes could be a critical part in the progression of IDC and serve as prognosis indicators. Complmentarity between CDK1 and three drugs, Aminophenazone, Pomalidomide and the Rosoxacin, implies novel pharmacological value of those drugs in breast cancer.

METHODS {#s4}
=======

Microarray data {#s4_1}
---------------

The microarray data GSE21422 was collected from Gene Expression Omnibus(GEO) which was built upon GPL570 platform. This platform was stored by Schaefer C et al \[[@R13]\] and houses 19 microarray data of nine DCIS, 5 invasive ductal carcinoma(IDC) and 5 healthy control samples obtained from patients with breast reduction surgery.

Data preprocessing {#s4_2}
------------------

The original CEL data were imported into R and affy package was implemented for background correction and normalization. The expression of genes corresponding to multi probes were summarized. mas5calls in Affy was run to filter out samples with no gene expression.

Differentially expressed genes selection {#s4_3}
----------------------------------------

DEGs between 5 healthy samples and 9 DCIS samples were identified using Limma package \[[@R14]\]. The FDR was set to 0.01 and those genes with \|log~2~ fold change \| \> =2 were regarded as differentially expression genes (DEGs).

Functional annotation and pathway analysis of DEGs {#s4_4}
--------------------------------------------------

Database for Annotation, Visualization, and Integrated Discovery (DAVID) is a web-server that combines functional genomic annotations with intuitive graphical summaries \[[@R15]\]. Gene lists or protein identifiers were rapidly annotated and categorized using comprehensive categorical data from Gene Ontology (GO), protein domain, and biochemical pathway membership. To investigate the inter-connection between pathways involved in pathogical mechanism of DCIS, GO and Pathway enrichment analysis on DEGs were performed with the DAVID analysis system, significance level p\<= 0.05.

Protein interaction networks analysis {#s4_5}
-------------------------------------

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) \[[@R16]\] database (<http://string-db.org/>) was used to analyze protein interactions. STRING has advantages in that it aggregates most of the available information on protein-protein associations, which were benchmarked and scored against a common reference of functional partnership annotated at KEGG. There are more than 1100 organisms in extensive protein connection with global data. In this research, protein-protein interaction (PPI) network of DEGs was constructed based on STRING database where the interaction score above 0.4 was considered as *de facto* interaction.

Protein preparation for docking {#s4_6}
-------------------------------

The structure of the CDK1 in complex with CYCLINB1 and CKS2 \[PDB ID: 4YC3\] was used in the docking calculations. The cofactors, ions and water molecules were removed from this complex. then the CYCLINB1 and CSK2 were also removed. The hydrogen atoms of the protein were added and optimized by the REDUCE. The active site of the CDK1 was obtained from the FTMAP server, the orientations for hydroxy groups in selected binding residues were modified to conform to the proton positions determined by the HBUILD module in CHARMM.

Docking calculations {#s4_7}
--------------------

Virtural screening was performed to identify molecules that could bind to the active site of the CDK1. Docking of all compounds (26,504 compounds) downloaded from the lead-like subset of ZINC database was performed using DOCK 3.6 program. Complementarity of each ligand pose is scored as the sum of the receptor-ligand electrostatic and van der Waals interaction energy and corrected for ligand desolvation. Partial charges from the united-atom AMBER force field were used for all receptor atoms except for Serine, for which the dipole moment was increased as previously described to boost electrostatic scores for poses in polar contact with these important residues.
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